DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2024” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Parkinson’s Disease Research. Learn more about our innovative pipeline today! @ Parkinson’s Disease Pipeline Outlook
Key Takeaways from the Parkinson’s Disease Pipeline Report
- June 2024:- Cerevance Beta Inc.- This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson’s Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
- June 2024:- S.Biomedics Co., Ltd.- A Single Center, Open, Single Dosing, Dose-escalation, Phase 1/2a Study to Evaluate the Safety and Exploratory Efficacy of Embryonic Stem Cell-derived A9 Dopamine Progenitor Cell (A9-DPC) Therapy in Patients With Parkinson’s Disease
- DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
- The leading Parkinson’s Disease Companies such as Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals, and others.
- Promising Parkinson’s Disease Therapies such as Apomorphine Infusion, CVN424 150 mg, MT101-5, BIA 28-6156 10 mg, RO7046015, ND0612, and others.
Stay informed about the cutting-edge advancements in Parkinson’s Disease Treatments. Download for updates and be a part of the revolution in Neurology care @ Parkinson’s Disease Clinical Trials Assessment
Parkinson’s Disease Emerging Drugs Profile
- Tavapadon: Cerevel Therapeutics
Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. The drug is designed to improve motor symptoms by selectively targeting and binding to dopamine D1/D5 receptor subtypes and to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor over excitation and desensitization caused by full agonists, which can lead to dyskinesia’s and exacerbation of “off” time. Currently it is in Phase III stage of clinical trial evaluation to treat Parkinson’s disease.
- IkT-148009: Inhibikase Therapeutics
IkT-148009 is a potent, selective small-molecule, oral medication targeting the underlying biological mechanism with the goal of halting disease progression and reversing functional loss. The drug is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. IkT-148009 is currently being evaluated in the Phase II studies for the treatment of Parkinson’s disease.
- NLY01: Neuraly
NLY01 is a first-in-Class GLP-1R agonist for Neurodegenerative Disease. It is a pegylated exendin-4 analogue of glucagon like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood–brain barrier (BBB) and its receptor (GLP-1R) is highly expressed on glial cells. Currently the drug is being evaluated in Phase II for the treatment of Parkinson’s disease.
- PT320: Peptron
PT320 (Exenatide) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) belonging to the group of incretin mimetics. It is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster, and it is a 39-amino-acid peptide, inducing insulin secretion. Exenatide binds to the intact human GLP-1 receptor in a similar way to the human GLP-1. Currently the drug is being evaluated in Phase II for the treatment of Parkinson’s disease.
- BIIB094: Biogen
BIIB094, also known as ION859 is an investigational antisense medicine designed to inhibit the production of the leucine-rich repeat kinase 2 (LRRK2) protein as a potential therapy. It binds the mRNA for leucine-rich repeat kinase 2 and mediates its degradation. This results in lower LRRK2 protein levels. Currently the drug is being evaluated in Phase II for the treatment of Parkinson’s disease.
Learn more about Parkinson’s Disease Drugs opportunities in our groundbreaking Parkinson’s Disease Research and development projects @ Parkinson’s Disease Unmet Needs
Parkinson’s Disease Companies and Drugs
- Cerevel Therapeutics: Tavapadon
- Pharma Two B Ltd: P2B001
- Hoffman-La Roche: Prasinezumab
- FAScinate Therapeutics: KM-819
- Peptron: PT320
- Vaxxinity Inc.: UB-312
Parkinson’s Disease Market Drivers
- Increasing prevalence of Parkinson’s Disease patients
- Robust clinical-stage pipeline
Parkinson’s Disease Market Barriers
- Lack of awareness and delayed diagnosis
- Side effects associated with Parkinson’s disease treatment drugs
Discover the latest advancements in Parkinson’s Disease Treatment by visiting our website. Stay informed about how we’re transforming the future of Neurology @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspectives
Scope of the Parkinson’s Disease Pipeline Report
- Coverage- Global
- Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals
- Parkinson’s Disease Therapies- Apomorphine Infusion, CVN424 150 mg, MT101-5, BIA 28-6156 10 mg, RO7046015, ND0612, and others.
- Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Parkinson’s Disease Pipeline on our website @ Parkinson’s Disease Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Parkinson’s disease : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Tavapadon: Cerevel Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IkT-148009: Inhibikase Therapeutics
- Early Stage Products (Phase I )
- Product Name: Company Name
- Inactive Products
- Parkinson’s disease Key Companies
- Parkinson’s disease Key Products
- Parkinson’s disease – Unmet Needs
- Parkinson’s disease – Market Drivers and Barriers
- Parkinson’s disease – Future Perspectives and Conclusion
- Parkinson’s disease Analyst Views
- Parkinson’s disease Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/